表紙
市場調查報告書

癌症免疫療法的市場

Cancer Immunotherapy Market

出版商 Progressive Markets Research 商品編碼 511099
出版日期 內容資訊 英文 184 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症免疫療法的市場 Cancer Immunotherapy Market
出版日期: 2018年04月01日內容資訊: 英文 184 Pages
簡介

本報告提供全球癌症免疫療法的市場相關分析,服務概要和市場基本結構,主要的推動及阻礙市場要素,整體市場規模、佔有率趨勢預測 (過去3年、今後9年份),各類型、各用途、各地區的詳細趨勢,主要企業的簡介、業績、策略趨勢等調查。

第1章 摘要整理

第2章 簡介

第3章 市場環境

  • 成長促進因素:影響度分析
  • 阻礙因素與課題:影響度分析
  • 波特的五力分析
  • 市場佔有率分析:全球癌症免疫療法市場 (總計12年份)
    • 各類型
    • 各用途
    • 各地區

第4章 全球癌症免疫療法市場:各類型

  • 單株抗體
    • 市場規模的成果值 (過去3年份)
    • 市場規模的預測值 (今後9年份)
  • 免疫調節藥物
  • 癌症疫苗
  • 查核點抑制劑

第5章 全球癌症免疫療法市場:各用途

  • 乳癌
  • 肺癌
  • 直腸結腸癌 (大腸癌)
  • 前列腺癌
  • 黑色素瘤
  • 頭部、頸部癌
  • 其他

第6章 全球癌症免疫療法市場:各地區

  • 北美 (美國,加拿大,墨西哥)
  • 歐洲 (英國,德國,法國,西班牙,義大利等)
  • 亞太地區 (中國,日本,印度,澳洲,韓國等)
  • 南美、中東、非洲 (LAMEA:巴西,沙烏地阿拉伯,南非等)

第7章 企業簡介

  • Amgen
    • 概要
    • 財務分析,部門結構
    • 近幾年主要的動向
  • Astrazeneca
  • Bayer ag
  • F. Hoffman la-roche
  • Bristol-myers squibb
  • Janssen global services, llc
  • Eli lilly and company
  • Merck & co., inc.
  • Novartis
  • Pfizer inc.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PMR1140

CANCER IMMUNOTHERAPY MARKET - OVERALL INDUSTRY ANALYSIS

The global cancer immunotherapy market was valued at $57,256.2 million in 2017 and is expected to reach $166,714.5 million by 2025, registering a CAGR of 14.42% during the period, 2018-2025. Cancer is a concerning health issue globally and patients succumb to the disease every single day. Among the various modes of treatment, using the immune system to treat cancer or cancer immunotherapy has gained widespread importance in the recent years. Cancer immunotherapy deals with the interaction between cancer cells and the immune system. It harnesses certain components of the immune system to fight cancer. The treatment can be done in several ways. Some of them involve stimulating the body's immune system to work harder to attack cancer cells while some others involve providing the immune system with man-made immune system proteins to fight cancer cells. The various types of immunotherapy used to treat cancer include monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and other immunotherapies.

CANCER IMMUNOTHERAPY MARKET DRIVERS AND RESTRAINTS

The cancer immunotherapy market is a fiercely competitive one with several big players operating in the field. The report says that the rise in funding from various government and private organizations for carrying out R&D activities for cancer immunotherapy, growing incidence of cancer globally, rise in approvals for the clinical trials and the growing acceptance of cancer immunotherapy are driving the demand of the industry. On the other hand, the high cost associated with cancer immunotherapy restrains the industry growth.

KEY MARKET SEGMENTATION

Cancer Immunotherapy Market Segmentation:

By Type

  • Monoclonal Antibodies
  • Cytokines & Immunomodulators
  • Cancer Vaccines
  • Checkpoint Inhibitors

By Application

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Head and Neck Cancer
  • Others

By End User

  • Hospitals
  • Cancer Research Centers
  • Clinics

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

KEY MARKET PLAYERS

The report also focuses on the leading players in the cancer immunotherapy market, providing information such as company profiles, product and specification, capacity, production, price, revenue and contact information. The report also discloses information about the strategies adopted by the players which they use to sustain and grow in the market. The major players mentioned in the report include Novartis, AstraZeneca, Bristol-Myers Squibb, Amgen, F. Hoffman La-Roche, Eli Lilly and Company, Merck & Co., Inc., Janssen Global Services, LLC, Bayer AG, and Pfizer.

KEY TAKEAWAYS FROM THE CANCER IMMUNOTHERAPY MARKET REPORT

  • The report provides a comprehensive analysis of the cancer immunotherapy market, incorporating the market size, market share analysis, market classification, market comparison analysis, market status and forecast analysis, development trends in the market, and company profiles.
  • The report includes the current market trends and estimations for the period, 2018-2025 to identify the prevailing market opportunities across the various regions where the market has been analyzed.
  • The study includes the top investment pockets to assist stakeholders in identifying the cash cows of the industry.
  • The report includes an analysis of the factors that drive and impede the growth of the market.
  • Key manufacturers of the cancer immunotherapy market are profiled in the report along with the recent developments to understand the competitive landscape.
  • A comprehensive analysis of the market helps in assessing the growth strategies adopted by the key players over the past few years.

Table of Contents

1. Executive summary

  • 1.1. Key findings
  • 1.2. Market attractiveness and trend analysis
  • 1.3. Competitive landscape and recent industry development analysis

2. Introduction

  • 2.1. Report description
  • 2.2. Scope and definitions
  • 2.3. Research methodology

3. Market landscape

  • 3.1. Growth drivers
    • 3.1.1. Impact analysis
  • 3.2. Restrains and challenges
    • 3.2.1. Impact analysis
  • 3.3. Porters analysis
    • 3.3.1. Bargaining power of buyers
    • 3.3.2. Bargaining power of suppliers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Industry rivalry
    • 3.3.5. Threat of new entrants
  • 3.4. Global cancer immunotherapy market shares analysis, 2014-2025
    • 3.4.1. Global cancer immunotherapy market share by type, 2014-2025
    • 3.4.2. Global cancer immunotherapy market share by application, 2014-2025
    • 3.4.3. Global cancer immunotherapy market share by geography, 2014-2025

4. Global cancer immunotherapy market by type

  • 4.1. Monoclonal antibodies
    • 4.1.1. Historical market size by region, 2014-2016
    • 4.1.2. Market forecast by region, 2017-2025
  • 4.2. Immunomodulators
    • 4.2.1. Historical market size by region, 2014-2016
    • 4.2.2. Market forecast by region, 2017-2025
  • 4.3. Cancer vaccines
    • 4.3.1. Historical market size by region, 2014-2016
    • 4.3.2. Market forecast by region, 2017-2025
  • 4.4. Checkpoint inhibitors
    • 4.4.1. Historical market size by region, 2014-2016
    • 4.4.2. Market forecast by region, 2017-2025

5. Global cancer immunotherapy market by application

  • 5.1. Breast cancer
    • 5.1.1. Historical market size by region, 2014-2016
    • 5.1.2. Market forecast by region, 2017-2025
  • 5.2. Lung cancer
    • 5.2.1. Historical market size by region, 2014-2016
    • 5.2.2. Market forecast by region, 2017-2025
  • 5.3. Colorectal cancer
    • 5.3.1. Historical market size by region, 2014-2016
    • 5.3.2. Market forecast by region, 2017-2025
  • 5.4. Prostate cancer
    • 5.4.1. Historical market size by region, 2014-2016
    • 5.4.2. Market forecast by region, 2017-2025
  • 5.5. Melanoma
    • 5.5.1. Historical market size by region, 2014-2016
    • 5.5.2. Market forecast by region, 2017-2025
  • 5.6. Head and neck cancer
    • 5.6.1. Historical market size by region, 2014-2016
    • 5.6.2. Market forecast by region, 2017-2025
  • 5.7. Others
    • 5.7.1. Historical market size by region, 2014-2016
    • 5.7.2. Market forecast by region, 2017-2025

6. Global cancer immunotherapy market by geography

  • 6.1. North America
    • 6.1.1. U.S.
      • 6.1.1.1. Historical market size, 2014-2016
      • 6.1.1.2. Market forecast, 2017-2025
    • 6.1.2. Canada
      • 6.1.2.1. Historical market size, 2014-2016
      • 6.1.2.2. Market forecast, 2017-2025
    • 6.1.3. Mexico
      • 6.1.3.1. Historical market size, 2014-2016
      • 6.1.3.2. Market forecast, 2017-2025
  • 6.2. Europe
    • 6.2.1. UK
      • 6.2.1.1. Historical market size, 2014-2016
      • 6.2.1.2. Market forecast, 2017-2025
    • 6.2.2. Germany
      • 6.2.2.1. Historical market size, 2014-2016
      • 6.2.2.2. Market forecast, 2017-2025
    • 6.2.3. France
      • 6.2.3.1. Historical market size, 2014-2016
      • 6.2.3.2. Market forecast, 2017-2025
    • 6.2.4. Spain
      • 6.2.4.1. Historical market size, 2014-2016
      • 6.2.4.2. Market forecast, 2017-2025
    • 6.2.5. Italy
      • 6.2.5.1. Historical market size, 2014-2016
      • 6.2.5.2. Market forecast, 2017-2025
    • 6.2.6. Rest of Europe
      • 6.2.6.1. Historical market size, 2014-2016
      • 6.2.6.2. Market forecast, 2017-2025
  • 6.3. Asia-Pacific
    • 6.3.1. China
      • 6.3.1.1. Historical market size, 2014-2016
      • 6.3.1.2. Market forecast, 2017-2025
    • 6.3.2. Japan
      • 6.3.2.1. Historical market size, 2014-2016
      • 6.3.2.2. Market forecast, 2017-2025
    • 6.3.3. India
      • 6.3.3.1. Historical market size, 2014-2016
      • 6.3.3.2. Market forecast, 2017-2025
    • 6.3.4. Australia
      • 6.3.4.1. Historical market size, 2014-2016
      • 6.3.4.2. Market forecast, 2017-2025
    • 6.3.5. South Korea
      • 6.3.5.1. Historical market size, 2014-2016
      • 6.3.5.2. Market forecast, 2017-2025
    • 6.3.6. Rest of Asia-Pacific
      • 6.3.6.1. Historical market size, 2014-2016
      • 6.3.6.2. Market forecast, 2017-2025
  • 6.4. LAMEA
    • 6.4.1. Brazil
      • 6.4.1.1. Historical market size, 2014-2016
      • 6.4.1.2. Market forecast, 2017-2025
    • 6.4.2. Saudi Arabia
      • 6.4.2.1. Historical market size, 2014-2016
      • 6.4.2.2. Market forecast, 2017-2025
    • 6.4.3. South Africa
      • 6.4.3.1. Historical market size, 2014-2016
      • 6.4.3.2. Market forecast, 2017-2025
    • 6.4.4. Rest of LAMEA
      • 6.4.4.1. Historical market size, 2014-2016
      • 6.4.4.2. Market forecast, 2017-2025

7. Company profiles

  • 7.1. Amgen
    • 7.1.1. Overview
    • 7.1.2. Financials and business segments
    • 7.1.3. Recent developments
  • 7.2. Astrazeneca
    • 7.2.1. Overview
    • 7.2.2. Financials and business segments
    • 7.2.3. Recent developments
  • 7.3. Bayer ag
    • 7.3.1. Overview
    • 7.3.2. Financials and business segments
    • 7.3.3. Recent developments
  • 7.4. F. Hoffman la-roche
    • 7.4.1. overview
    • 7.4.2. Financials and business segments
    • 7.4.3. Recent developments
  • 7.5. Bristol-myers squibb
    • 7.5.1. Overview
    • 7.5.2. Financials and business segments
    • 7.5.3. Recent developments
  • 7.6. Janssen global services, llc
    • 7.6.1. overview
    • 7.6.2. Financials and business segments
    • 7.6.3. Recent developments
  • 7.7. Eli lilly and company
    • 7.7.1. Overview
    • 7.7.2. Financials and business segments
    • 7.7.3. Recent developments
  • 7.8. Merck & co., inc.
    • 7.8.1. overview
    • 7.8.2. Financials and business segments
    • 7.8.3. Recent developments
  • 7.9. Novartis
    • 7.9.1. Overview
    • 7.9.2. Financials and business segments
    • 7.9.3. Recent developments
  • 7.10. Pfizer inc.
    • 7.10.1. Overview
    • 7.10.2. Financials and business segments
    • 7.10.3. Recent developments

List of Tables

  • Table 1.Cancer Immunotherapy Market Share, by Type, 2014-2025
  • Table 2.Cancer Immunotherapy Market Share, by Application, 2014-2025
  • Table 3.Cancer Immunotherapy Market Share, by Region, 2014-2025
  • Table 4.Cancer Immunotherapy Market Value for Monoclonal Antibodies, by Region, 2017-2025, $million
  • Table 5.Cancer Immunotherapy Market Value for Immunomodulators, by Region, 2017-2025, $million
  • Table 6.Cancer Immunotherapy Market Value for Cancer Vaccines, by Region, 2017-2025, $million
  • Table 7.Cancer Immunotherapy Market Value for Checkpoint Inhibitors, by Region, 2017-2025, $million
  • Table 8.Cancer Immunotherapy Market Value for Breast Cancer, by Region, 2017-2025, $million
  • Table 9.Cancer Immunotherapy Market Value for Lung Cancer, by Region, 2017-2025, $million
  • Table 10.Cancer Immunotherapy Market Value for Colorectal Cancer, by Region, 2017-2025, $million
  • Table 11.Cancer Immunotherapy Market Value for Prostate Cancer, by Region, 2017-2025, $million
  • Table 12.Cancer Immunotherapy Market Value for Melanoma, by Region, 2017-2025, $million
  • Table 13.Cancer Immunotherapy Market Value for Head and Neck Cancer, by Region, 2017-2025, $million
  • Table 14.Cancer Immunotherapy Market Value for Others, by Region, 2017-2025, $million
  • Table 15.Cancer Immunotherapy Market Value for North America, by Country, 2014-2025, $million
  • Table 16.Cancer Immunotherapy Market Value for North America, by Type, 2014-2025, $million
  • Table 17.Cancer Immunotherapy Market Value for North America, by Application, 2014-2025, $million
  • Table 18.Cancer Immunotherapy Market Value for Europe, by Country, 2014-2025, $million
  • Table 19.Cancer Immunotherapy Market Value for Europe, by Type, 2014-2025, $million
  • Table 20.Cancer Immunotherapy Market Value for Europe, by Application, 2014-2025, $million
  • Table 21.Cancer Immunotherapy Market Value for Asia-Pacific, by Country, 2014-2025, $million
  • Table 22.Cancer Immunotherapy Market Value for Asia-Pacific, by Type, 2014-2025, $million
  • Table 23.Cancer Immunotherapy Market Value for Asia-Pacific, by Application, 2014-2025, $million
  • Table 24.Cancer Immunotherapy Market Value for LAMEA, by Country, 2014-2025, $million
  • Table 25.Cancer Immunotherapy Market Value for LAMEA, by Type, 2014-2025, $million
  • Table 26.Cancer Immunotherapy Market Value for LAMEA, by Application, 2014-2025, $million
  • Table 27. Amgen - Company Snapshot
  • Table 28. AstraZeneca - Company Snapshot
  • Table 29. Bayer AG - Company Snapshot
  • Table 30. F. Hoffman La-Roche - Company Snapshot
  • Table 31. Janssen Global Services, LLC - Company Snapshot
  • Table 32. Eli Lilly and Company - Company Snapshot
  • Table 33. Merck & Co., Inc. - Company Snapshot
  • Table 34. Novartis - Company Snapshot
  • Table 35. Pfizer - Company Snapshot
  • Table 36. Bristol-Myers Squibb - Company Snapshot

List of Figures

  • Figure 1.Cancer Immunotherapy: Monoclonal Antibodies Market Value, 2014-2016, $million
  • Figure 2.Cancer Immunotherapy: Immunomodulators Market Value, 2014-2016, $million
  • Figure 3.Cancer Immunotherapy: Cancer Vaccines Market Value, 2014-2016, $million
  • Figure 4.Cancer Immunotherapy: Checkpoint Inhibitors Market Value, 2014-2016, $million
  • Figure 5.Cancer Immunotherapy: Breast Cancer Market Value, 2014-2016, $million
  • Figure 6.Cancer Immunotherapy: Lung Cancer Market Value, 2014-2016, $million
  • Figure 7.Cancer Immunotherapy: Colorectal Cancer Market Value, 2014-2016, $million
  • Figure 8.Cancer Immunotherapy: Prostate Cancer Market Value, 2014-2016, $million
  • Figure 9.Cancer Immunotherapy: Melanoma Market Value, 2014-2016, $million
  • Figure 10.Cancer Immunotherapy: Head and Neck Cancer Market Value, 2014-2016, $million
  • Figure 11.Cancer Immunotherapy: Others Market Value, 2014-2016, $million
  • Figure 12.Cancer Immunotherapy: U.S. Market Value, 2014-2016, $million
  • Figure 13.Cancer Immunotherapy: U.S. Market Value, 2017-2025, $million
  • Figure 14.Cancer Immunotherapy: Canada Market Value, 2014-2016, $million
  • Figure 15.Cancer Immunotherapy: Canada Market Value, 2017-2025, $million
  • Figure 16.Cancer Immunotherapy: Mexico Market Value, 2014-2016, $million
  • Figure 17.Cancer Immunotherapy: Mexico Market Value, 2017-2025, $million
  • Figure 18.Cancer Immunotherapy: UK Market Value, 2014-2016, $million
  • Figure 19.Cancer Immunotherapy: UK Market Value, 2017-2025, $million
  • Figure 20.Cancer Immunotherapy: Germany Market Value, 2014-2016, $million
  • Figure 21.Cancer Immunotherapy: Germany Market Value, 2017-2025, $million
  • Figure 22.Cancer Immunotherapy: France Market Value, 2014-2016, $million
  • Figure 23.Cancer Immunotherapy: France Market Value, 2017-2025, $million
  • Figure 24.Cancer Immunotherapy: Spain Market Value, 2014-2016, $million
  • Figure 25.Cancer Immunotherapy: Spain Market Value, 2017-2025, $million
  • Figure 26.Cancer Immunotherapy: Italy Market Value, 2014-2016, $million
  • Figure 27.Cancer Immunotherapy: Italy Market Value, 2017-2025, $million
  • Figure 28.Cancer Immunotherapy: Rest of Europe Market Value, 2014-2016, $million
  • Figure 29.Cancer Immunotherapy: Rest of Europe Market Value, 2017-2025, $million
  • Figure 30.Cancer Immunotherapy: China Market Value, 2014-2016, $million
  • Figure 31.Cancer Immunotherapy: China Market Value, 2017-2025, $million
  • Figure 32.Cancer Immunotherapy: Japan Market Value, 2014-2016, $million
  • Figure 33.Cancer Immunotherapy: Japan Market Value, 2017-2025, $million
  • Figure 34.Cancer Immunotherapy: India Market Value, 2014-2016, $million
  • Figure 35.Cancer Immunotherapy: India Market Value, 2017-2025, $million
  • Figure 36.Cancer Immunotherapy: Australia Market Value, 2014-2016, $million
  • Figure 37.Cancer Immunotherapy: Australia Market Value, 2017-2025, $million
  • Figure 38.Cancer Immunotherapy: South Korea Market Value, 2014-2016, $million
  • Figure 39.Cancer Immunotherapy: South Korea Market Value, 2017-2025, $million
  • Figure 40.Cancer Immunotherapy: Rest of Asia-Pacific Market Value, 2014-2016, $million
  • Figure 41.Cancer Immunotherapy: Rest of Asia-Pacific Market Value, 2017-2025, $million
  • Figure 42.Cancer Immunotherapy: Brazil Market Value, 2014-2016, $million
  • Figure 43.Cancer Immunotherapy: Brazil Market Value, 2017-2025, $million
  • Figure 44.Cancer Immunotherapy: Saudi Arabia Market Value, 2014-2016, $million
  • Figure 45.Cancer Immunotherapy: Saudi Arabia Market Value, 2017-2025, $million
  • Figure 46.Cancer Immunotherapy: South Africa Market Value, 2014-2016, $million
  • Figure 47.Cancer Immunotherapy: South Africa Market Value, 2017-2025, $million
  • Figure 48.Cancer Immunotherapy: Rest of LAMEA Market Value, 2014-2016, $million
  • Figure 49.Cancer Immunotherapy: Rest of LAMEA Market Value, 2017-2025, $mill
Back to Top